almonertinib   Click here for help

GtoPdb Ligand ID: 11136

Synonyms: Ameile | Egfr T790M inhibitor HS-10296 | example 26 [WO2016054987A1] | HS10296
Approved drug
almonertinib is an approved drug (China (2020))
Compound class: Synthetic organic
Comment: Almonertinib (HS-10296) is an orally bioavailable, third generation inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR) with activity at the EGFRT790M mutant [1]. In assays using triple-negative breast cancer MDA-MB-231 cells, HS-10296 inhibits signalling via the EGFR/PI3K/AKT pathway which results in reduced proliferation and induction of autophagy and apoptosis. HS-10296 was developed by Hansoh Pharmaceutical, and ex-China rights were licensed to EQRx in mid-2020.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 87.55
Molecular weight 525.29
XLogP 4.14
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C2CC2)c(cc1N(CCN(C)C)C)OC
Isomeric SMILES C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C2CC2)c(cc1N(CCN(C)C)C)OC
InChI InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
InChI Key DOEOECWDNSEFDN-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Almonertinib is approved in China (March 2020) as second-line treatment for patients with EGFRT790M mutation-positive non-small cell lung cancer (NSCLC).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03849768 A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients Phase 3 Interventional Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT03904823 A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC Phase 2 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT02981108 A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Phase 1/Phase 2 Interventional Jiangsu Hansoh Pharmaceutical Co., Ltd.